RESUMO
The aim of this observational prospective study was to compare multiple embryological and pregnancy outcomes for vitrified oocytes against the same outcomes using vitrified embryos in patients at risk for ovarian hyperstimulation syndrome. Ninety-six patients were included and allocated to vitrification of oocytes (Group 1) or embryos (Group 2). No statistical differences in baseline characteristics between groups were detected. Implantation rate was 30.6% versus 33.1%, and clinical pregnancy rate was 41.9% versus 7.1% in groups 1 and 2, respectively. A higher clinical spontaneous abortion rate occurred in group 2 (9.7% versus 21.9% for groups 1 and 2, respectively), but the same cumulative clinical pregnancy rate was observed after three embryo transfers (62.0% in group 1 and 69.6% in group 2). The ongoing pregnancy rate per patient was similar in both groups (56.0% and 54.3% in groups 1 and 2, respectively). Also, live birth rate per stimulation was similar (72.0% and 69.6% in groups 1 and 2, respectively). No differences were observed in outcomes according to vitrification timing. Oocyte vitrification achieved the same live birth rate as embryo vitrification.
Assuntos
Transferência Embrionária/métodos , Oócitos/citologia , Vitrificação , Aborto Espontâneo/etiologia , Adulto , Criopreservação/métodos , Implantação do Embrião , Endométrio/patologia , Feminino , Fertilização in vitro , Humanos , Síndrome de Hiperestimulação Ovariana/prevenção & controle , Gravidez , Resultado da Gravidez , Taxa de Gravidez , Injeções de Esperma Intracitoplásmicas/métodos , Fatores de Tempo , Resultado do TratamentoRESUMO
In this observational trial, we compared the impact on two different strategies, egg vitrification (n = 152) obtained after triggering final oocyte maturation with GnRH agonists and transferring the embryos at a later stage, with classical coasting (n = 96) to avoid OHSS in patients at risk due to high response to COH. Our results show that oocyte vitrification after GnRH agonists triggering is a highly attractive, safe, and efficient alternative to postpone embryo transfer in patients at high risk of OHSS, resulting in decreased risk for the patient and a better cycle outcome (pregnancy rate 50% vs 29.5%).